In short
Clinical trials are studying Ag-946 in people with anemia due to lower-risk myelodysplastic syndromes. The trials are looking at whether Ag-946 can improve hemoglobin levels and help participants become transfusion independent. They are in Phase 2 and include adults with this blood disorder.
Key points
- Clinical trials of Ag-946 are studying anemia due to lower-risk myelodysplastic syndromes. The available study is a Phase 2 interventional trial with 131 planned participants. Researchers are looking at whether Ag-946 can raise hemoglobin levels and help people become transfusion independent. The trial includes a proof-of-concept part and a part focused on transfusion independence. It is designed for people with lower-risk myelodysplastic syndromes, including some with a low transfusion burden.
Clinical trial overview
The available study of Ag-946 is being done in people with anemia due to lower-risk myelodysplastic syndromes, a blood disorder where the bone marrow does not make healthy blood cells well enough.
This trial is designed to see whether Ag-946 can improve blood counts and reduce the need for transfusions in this patient group.
Study design and phase
This is an interventional study, which means researchers give the study treatment and then measure the results.
The trial is in Phase 2, a stage that looks for early signs that a treatment may work while continuing to study its effects.
The study includes two parts: Phase 2a and Phase 2b. Phase 2a is meant to establish proof-of-concept, which means early evidence that the treatment may help.
Phase 2b focuses on transfusion independence, which means going without blood transfusions for a planned time.
Who can participate
The trial is for participants with lower-risk myelodysplastic syndromes and anemia.
One part of the study focuses on participants with a low transfusion burden, meaning they need transfusions less often.
The study planned enrollment is 131 participants.
What the trials measure
The main hemoglobin response outcome checks whether hemoglobin rises by at least 1.5 g/dL from baseline, based on the average level from Week 8 through Week 16.
Baseline means the starting point before treatment begins.
The study also measures transfusion independence, which means being transfusion-free for at least 8 consecutive weeks during the core period.
In Phase 2a, transfusion independence is measured in participants with low transfusion burden only.
In Phase 2b, the trial measures transfusion independence for at least 8 consecutive weeks during the core period.
Trial details at a glance
| Trial ID | Status | Phase | Condition | Enrollment | Main endpoints |
|---|---|---|---|---|---|
| NCT05490446 | Authorised | Phase 2 | Anemia due to lower-risk myelodysplastic syndromes | 131 | Hemoglobin response; transfusion independence |
What these trials may mean for patients
For patients, this study is trying to answer a simple question: can Ag-946 help improve anemia and reduce transfusion needs in lower-risk myelodysplastic syndromes?
The trial is still an early-stage study, so it is mainly focused on learning whether the treatment shows enough benefit to support later research.